Brett S. AbrahamsBScH, PhD
Brett S. Abrahams, Ph.D. is Vice President, Research & Development at Magnolia Neurosciences Corporation. Before joining Magnolia, Dr. Abrahams was Senior Director and Head, Pre-Clinical Biology at Ovid Therapeutics, Inc. (NASDAQ: OVID). At Ovid Dr. Abrahams’ mandate was to drive all non-clinical R&D including joint efforts with Takeda Pharmaceutical Company Ltd. Dr. Abrahams led pre-clinical development of OV329, a novel GABA-AT inhibitor, and was part of the team that showed significant clinical benefit of OV101/Gaboxadol in Angelman syndrome. Prior to joining Ovid, Dr. Abrahams was a member of the faculty in the Departments of Genetics and Neuroscience at the Albert Einstein College of Medicine, where he retains an adjunct appointment. His lab used genomic strategies to identify genes that increase risk for neurocognitive disorders and then studied these genes in both model systems and patients. Before this, he was a Post-Doctoral Fellow and later a Visiting Assistant Professor in the Department of Neurology at UCLA. Research Dr. Abrahams has led has resulted in new insights into disease biology, identified novel disease biomarkers, given rise to licensed technology used for clinical evaluation, and has shaped clinical trials in children and adults. Results from scientific research have been widely disseminated through publication of high impact peer reviewed manuscripts and coverage in the popular press (ABC News, BBC News, Reuters, The Telegraph, and Time Magazine).